Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.59
(
-0.06%
)
Bitcoin
74,058.72
(
0.16%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 127194

Friday, 09/23/2011 12:50:27 PM

Friday, September 23, 2011 12:50:27 PM

Post# of 257253
For Bayer, specifically, the way the Xarelto chips have fallen is quite favorable. In the EU, where Bayer owns 100% of the commercial rights, Xarelto is now approved* for all major indications: AF/stroke prevention, VTE prevention, and acute VTE treatment. US approval for AF/stroke prevention remains in doubt and no US submission has even been made in acute VTE treatment; however, Bayer has only 30% of the commercial rights for Xarelto in the US—JNJ has the rest.

*Pending rubber-stamping for the indications endorsed by the CHMP today.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now